Age-related macular degeneration (AMD) is a progressive eye condition affecting the macula, the central portion of the retina responsible for sharp, central vision. It is a leading cause of vision loss among individuals aged 50 and above. While treatments like anti-VEGF injections have been widely used for wet AMD, photodynamic therapy (PDT) offers an alternative approach for certain forms of the disease. In this comprehensive guide, we’ll explore the intricacies of photodynamic therapy for macular degeneration, including its mechanism, indications, effectiveness, considerations, and potential risks.

Age-related macular degeneration (AMD) is classified into two main types: dry AMD and wet AMD. Dry AMD is characterized by the presence of drusen, small yellow deposits that accumulate beneath the retina. While dry AMD progresses slowly and may cause gradual vision loss, wet AMD involves the growth of abnormal blood vessels beneath the retina, leading to sudden and severe vision impairment.

Photodynamic therapy (PDT) is a specialized treatment for various medical conditions, including age-related macular degeneration (AMD). It involves the use of a light-sensitive drug called verteporfin (brand name Visudyne) and a low-energy laser.

The process begins with the intravenous injection of verteporfin, which circulates throughout the body and selectively accumulates in abnormal blood vessels, such as those present in the retina in cases of wet AMD. Once the drug has had sufficient time to concentrate in the targeted areas, a low-energy laser is directed at the affected area of the eye.

When the laser light interacts with the verteporfin, it triggers a reaction that produces a toxic form of oxygen. This oxygen selectively damages the abnormal blood vessels, causing them to close off without significantly harming surrounding healthy tissue. By sealing off these vessels, PDT aims to reduce the leakage of fluid and blood into the retina, thereby slowing the progression of AMD and preserving vision.

Photodynamic therapy is primarily indicated for cases of wet AMD where there is evidence of predominantly classic choroidal neovascularization (CNV) lesions. Classic CNV lesions are characterized by well-defined, mature blood vessels beneath the retina.

PDT has been shown to be effective in reducing the leakage and growth of abnormal blood vessels in the retina, thereby helping to preserve vision and slow the progression of wet AMD. However, its effectiveness may vary depending on factors such as lesion size, location, and the presence of other retinal pathologies.

It’s important to note that PDT is often used in combination with other treatment modalities, such as anti-VEGF therapy, to achieve optimal outcomes in wet AMD management.

While photodynamic therapy can be an effective treatment option for certain cases of AMD, there are several considerations and potential risks associated with the procedure.

• Visual disturbances: Following PDT, patients may experience transient visual disturbances such as blurred vision, sensitivity to light, and changes in color perception. These effects typically resolve within a few days after treatment.
• Risk of damage to surrounding tissue: If the laser is not precisely targeted during PDT, there is a risk of damage to surrounding healthy retinal tissue. Therefore, careful monitoring and precise delivery of the laser are essential to minimize this risk.
• Contraindications: PDT may not be suitable for all individuals with wet AMD, particularly those with certain retinal conditions or contraindications to verteporfin. Patients should undergo thorough evaluation and consultation with an ophthalmologist to determine the most appropriate treatment approach for their specific case.

Photodynamic therapy represents a valuable therapeutic option for selected cases of wet AMD, offering a targeted approach to the management of abnormal blood vessel growth in the retina. While PDT may not be a standalone solution for all forms of AMD, it can complement existing treatment modalities and contribute to preserving vision and improving patient outcomes. As research and technology continue to advance, photodynamic therapy holds promise as part of the multifaceted approach to combating age-related macular degeneration and preserving visual function.

World Eye Care Foundation’s eyecare.live brings you the latest information from various industry sources and experts in eye health and vision care. Please consult with your eye care provider for more general information and specific eye conditions. We do not provide any medical advice, suggestions or recommendations in any health conditions.